The Role of PD-L1 in Lung Cancer: From Biology to Clinical Application - PubMed
6 hours ago
- #lung cancer
- #biomarker
- #immunotherapy
- Lung cancer is the leading cause of cancer death, with non-small cell lung cancer (NSCLC) making up 85% and small cell lung cancer (SCLC) 15% of cases.
- Immunotherapies, especially PD-1/PD-L1 inhibitors, have significantly advanced lung cancer treatment by blocking the interaction to restore antitumor immunity.
- PD-L1, normally involved in immune tolerance, is often overexpressed in tumors, aiding immune evasion; its expression level via immunohistochemistry is a key predictive biomarker for immunotherapy response.
- PD-L1 expression is heterogeneous and influenced by biological, clinical, and technical factors, complicating its use as a biomarker.
- This review covers the biology of PD-L1 in lung cancer, its expression patterns, regulatory mechanisms, assessment methods, and clinical relevance in guiding immunotherapy.